Pharvaris Past Earnings Performance
Past criteria checks 0/6
Pharvaris's earnings have been declining at an average annual rate of -40.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
-40.5%
Earnings growth rate
6.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -44.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Pharvaris makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -132 | 42 | 86 |
| 30 Jun 24 | 0 | -114 | 37 | 79 |
| 31 Mar 24 | 0 | -106 | 34 | 70 |
| 31 Dec 23 | 0 | -101 | 31 | 66 |
| 30 Sep 23 | 0 | -107 | 30 | 63 |
| 30 Jun 23 | 0 | -92 | 31 | 59 |
| 31 Mar 23 | 0 | -83 | 31 | 58 |
| 31 Dec 22 | 0 | -76 | 29 | 57 |
| 30 Sep 22 | 0 | -49 | 27 | 52 |
| 30 Jun 22 | 0 | -50 | 23 | 47 |
| 31 Mar 22 | 0 | -53 | 20 | 41 |
| 31 Dec 21 | 0 | -43 | 18 | 36 |
| 30 Sep 21 | 0 | -41 | 15 | 33 |
| 30 Jun 21 | 0 | -38 | 12 | 29 |
| 31 Mar 21 | 0 | -29 | 8 | 25 |
| 31 Dec 20 | 0 | -26 | 5 | 20 |
| 30 Sep 20 | 0 | -19 | 4 | 14 |
| 31 Dec 19 | 0 | -8 | 2 | 6 |
Quality Earnings: 9EN is currently unprofitable.
Growing Profit Margin: 9EN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9EN is unprofitable, and losses have increased over the past 5 years at a rate of 40.5% per year.
Accelerating Growth: Unable to compare 9EN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9EN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 9EN has a negative Return on Equity (-44.55%), as it is currently unprofitable.